Principal Investigator: Ali Naji, Michael Rickels

Study Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TV+66 in Subjects Who Have Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

Purpose:
Alleviate severe hypoglycemic events in patients with Type 1 diabetics

Brief Description
Stem cell derived islet cells would be transplanted via the portal vein in the liver in Type 1 diabetics who have severe hypoglycemic episodes.

Eligibility
Type 1 diabetic 18-65 years of age, Blood Group A or AB, having had at least 2 episodes of severe hypoglycemia in the past year, Hemoglobin A1c between 7 and 9%

Compensation (if applicable)
Travel and hotel accommodations provided along with stipends for visits

Name: Eileen Markmann
Phone: (215) 872-4220
Email: markmann@pennmedicine.upenn.edu